Real-World Outcome of Psoriasis Patients in Korea on Adalimumab
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Acronyms RAPSODI
- Sponsors AbbVie
- 23 Oct 2018 Planned End Date changed from 1 Nov 2018 to 25 Mar 2019.
- 23 Oct 2018 Planned primary completion date changed from 1 Nov 2018 to 25 Mar 2019.
- 08 Aug 2018 Status changed from recruiting to active, no longer recruiting.